...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer
【24h】

Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer

机译：辐射肺炎病史与间质肺病发作，患者预科晚期非小细胞肺癌患者进展生存

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Nivolumab has a promising efficacy for patients with non-small-cell lung cancer (NSCLC) as second-line or later treatment, and after radiotherapy as abscopal effect. However, the effects of radiation pneumonitis history before nivolumab have not been clarified. Therefore, we retrospectively analyzed the correlation of a history of radiation pneumonitis before nivolumab with onset of interstitial lung disease (ILD) and progression-free survival (PFS) after nivolumab treatment in patients with previously treated NSCLC. Patients and Methods: A total of 201 patients treated with nivolumab were retrospectively reviewed. We collected clinical data of patients at the time of starting nivolumab and we evaluated ILD incidence and PFS in relation to patient characteristics, including radiation pneumonitis history. Results: The median age was 68 years; 135 patients were men, 157 had a smoking history, and 153 had performance status of 0 or 1. Thirty-four patients experienced radiation pneumonitis before nivolumab, and 50 patients received radiotherapy to the chest (31 patients received curative radiotherapy). The overall median PFS was 2.8 months and the overall ILD rate was 12.4%. Higher ILD incidence was observed in the group with a history of radiation pneumonitis (26.5%) compared to the group without radiation pneumonitis (9.6%). The median PFS was 3.6 and 2.3 months, respectively. On multivariate analysis, a history of radiation pneumonitis was also significantly correlated with good PFS (p= 0.023). Conclusion: Although increasing the risk of ILD, a history of radiation pneumonitis before nivolumab also contributes to the prolongation of PFS after nivolumab.
机译：背景/目的：Nivolumab对非小细胞肺癌（NSCLC）作为第二线或更晚治疗的患者具有有希望的疗效，并且放疗后作为俯视效果。然而，尚未澄清辐射肺炎史的效果。因此，我们回顾性地分析了在患有先前治疗的NSCLC患者的Nivolumab治疗后Nivolumab前辐射肺炎前的辐射肺炎历史的相关性。患者和方法：回顾性审查了患有Nivolumab治疗的201例患者。我们在起始幼虫病时收集了患者的临床数据，我们评估了与患者特征有关的ILD发病率和PFS，包括辐射肺炎史。结果：中位年龄为68岁; 135名患者是男性，157例患有吸烟历史，153例具有0或1. 34名患者的性能状况，患有粪便前的辐射肺炎，50名患者接受胸部放射治疗（31名患者治疗药物治疗）。整体中位数PFS为2.8个月，总体速度率为12.4％。在没有辐射肺炎的组（9.6％）的基团相比，辐射肺炎历史（26.5％）观察到较高的ILD发病率。中位数PFS分别为3.6和2.3个月。在多变量分析上，辐射肺炎的历史也与良好的PFS显着相关（P = 0.023）。结论：虽然增加了ILD的风险，但Nivolumab前的辐射肺炎史也有助于Nivolumab后的PFS延长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号